Novartis Q4 Results
Content
Click below to navigate
through the document
Company overview
Financial review
Conclusions
Appendix
References
For Novartis and Sandoz shareholders since October 3, 2023,
USD 28.6bn (+13.9%) of value has been created
Market capitalization growth since the Sandoz spin-off
Total market capitalization 1,2 (in USD bn)
Novartis
Sandoz
Day before
spin-off
Day of
spin-off
As of Jan 30,
2024
Sandoz spin-off highlights
.
Completed the separation of Sandoz to create an
FINANCIAL PROFILE
independent company by way of 100% spin-off (Oct 4, 2023)
• Shares of Sandoz are listed on the SIX Swiss Exchange
and traded OTC in the US
↓
↑
+28.6
(+13.9%)
+3.1
(+1.5%)
233.7
219.3
205.1
208.2
196.9
11.3
14.5
Novartis on
Novartis and Sandoz
Novartis and Sandoz
October 3, 2023
on October 4, 2023
on January 30, 2024
.
Novartis continues with its consistently growing annual
dividend with no re-basing post the Sandoz spin-off
1. Market capitalization of Novartis on October 3, 2023 is based on closing share price and outstanding shares of 2,055,060,483 (as per October 3); market capitalization for Novartis and Sandoz on October 4, 2023 are based on opening share
prices on October 4, outstanding shares of 2,055,060,483 for Novartis and 431,000,000 shares for Sandoz; market capitalization for Novartis and Sandoz on January 30, 2024 are based on closing share prices on January 30, outstanding shares
as of December 31, 2023 of 2,044,033,986 for Novartis and 431,000,000 shares for Sandoz. 2. USD values based on USD/CHF exchange rates as per the respective days; source: Bloomberg.
□ NOVARTIS | Reimagining Medicine.
Novartis Q4 Results | January 31, 2024
29View entire presentation